In addition to its acute glucose-lowering effects on the HPA axis, chronic FGF19 treatment has also been shown to result in increased energy expenditure, reduced food intake and lower body weight2, 3, which also likely contributes to its efficacy at improving glycaemia in chronically treated rodent models of obesity and diabetes. This evidence concerns the gene FGF19 and obesity due to melanocortin 4 receptor deficiency.